Clinical Trials Logo
  1. Home
  2. Carcinoma, Non-Small-Cell Lung
  3. NCT00553254

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Carcinoma, Non Small Cell Lung Clinical Trial

Official title:
A PHASE 1/2, OPEN-LABEL, SINGLE ARM TRIAL TO DETERMINE THE RECOMMENDED PHASE 2 DOSE AND EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS IN KOREA WITH KRAS WILD TYPE ADVANCED NSCLC, WHICH IS REFRACTORY TO CHEMOTHERAPY AND ERLOTINIB OR GEFITINIB

Clinical Trial Summary

To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00553254
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date February 5, 2008
Completion date July 17, 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02135211 - Healthy Directions After Lung Surgery Pilot N/A
Completed NCT00191230 - Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer Phase 2
Withdrawn NCT01004419 - Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer Phase 1
Completed NCT01671332 - Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer Phase 2
Terminated NCT00905801 - Computed Tomography (CT) Perfusion Imaging of Lung Cancer N/A
Recruiting NCT00184964 - Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis N/A
Completed NCT00191256 - Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer Phase 2
Completed NCT00954278 - Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer Phase 1
Terminated NCT01282151 - TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer Phase 3
Terminated NCT01088906 - Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC Phase 2
Completed NCT01469000 - A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Phase 2
Withdrawn NCT00934076 - Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT00798720 - Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer Phase 2
Terminated NCT01891669 - A Study Of PF-06263507 In Patients With Advanced Solid Tumors Phase 1
Completed NCT00160069 - Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer Phase 2
Completed NCT00548093 - PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib Phase 2